The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer

被引：79

作者：

Sheikhbahaei, Sara ^{[1
]}

Mena, Esther ^{[1
]}

Yanamadala, Anusha ^{[1
]}

Reddy, Siddaling ^{[1
]}

Solnes, Lilja B. ^{[1
]}

Wachsmann, Jason ^{[2
]}

Subramaniam, Rathan M. ^{[1
,2
,3
]}

机构：

[1] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21218 USA

[2] Univ Texas Southwestern Med Ctr Dallas, Dept Radiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA

[3] Univ Texas Southwestern Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA

来源：

AMERICAN JOURNAL OF ROENTGENOLOGY | 2017年 / 208卷 / 02期

基金：

美国国家卫生研究院;

关键词：

FDG PET/CT; follow-up; lung cancer; recurrence detection; therapy assessment; POSITRON-EMISSION-TOMOGRAPHY; SMALL-CELL LUNG; STEREOTACTIC BODY RADIOTHERAPY; COMPUTED-TOMOGRAPHY; F-18-FDG PET/CT; NEOADJUVANT THERAPY; PULMONARY NODULES; TUMOR HYPOXIA; DIAGNOSTIC PERFORMANCE; 1ST-LINE CHEMOTHERAPY;

D O I：

10.2214/AJR.16.16532

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

OBJECTIVE. The purpose of this article is to summarize the evidence regarding the role of FDG PET/CT in treatment response assessment and surveillance of lung cancer and to provide suggested best practices. CONCLUSION. FDG PET/CT is a valuable imaging tool for assessing treatment response for patients with lung cancer, though evidence for its comparative effectiveness with chest CT is still evolving. FDG PET/CT is most useful when there is clinical suspicion or other evidence for disease recurrence or metastases. The sequencing, cost analysis, and comparative effectiveness of FDG PET/CT and conventional imaging modalities in the follow-up setting need to be investigated.

引用

页码：420 / 433

页数：14

共 89 条

[1]

American Cancer Society (ACS), LUNG CANC

[2]

[Anonymous], 2016, NCCN Clin Pract Guidel Oncol

[3]

[Anonymous], RADIOTHER ONCOL

[4]

[Anonymous], 2014, World Cancer Report

[5] Follow-up or Surveillance 18F-FDG PET/CT and Survival Outcome in Lung Cancer Patients [J].

Antoniou, Alexander J. ;

Marcus, Charles ;

Tahari, Abdel K. ;

Wahl, Richard L. ;

Subramaniam, Rathan M. .

JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (07) :1062-1068

[6] Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET [J].

Arvold, Nils D. ;

Heidari, Pedram ;

Kunawudhi, Anchisa ;

Sequist, Lecia V. ;

Mahmood, Umar .

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2016, 15 (02) :234-242

[7] Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC [J].

Bahce, I. ;

Vos, C. G. ;

Dickhoff, C. ;

Hartemink, K. J. ;

Dahele, M. ;

Smit, E. F. ;

Boellaard, R. ;

Hoekstra, O. S. ;

Thunnissen, E. .

LUNG CANCER, 2014, 85 (02) :205-212

[8] Diagnostic Performance of Dual-time 18F-FDG PET in the Diagnosis of Pulmonary Nodules: A Meta-analysis [J].

Barger, Richard L., Jr. ;

Nandalur, Kiran R. .

ACADEMIC RADIOLOGY, 2012, 19 (02) :153-158

[9] Utility of Routine PET Imaging to Predict Response and Survival After Induction Therapy for Non-Small Cell Lung Cancer [J].

Barnett, Stephen A. ;

Downey, Robert J. ;

Zheng, Junting ;

Plourde, Gabriel ;

Shen, Ronglai ;

Chaft, Jamie ;

Akhurst, Timothy ;

Park, Bernard J. ;

Rusch, Valerie W. .

ANNALS OF THORACIC SURGERY, 2016, 101 (03) :1052-1059

[10] Residual 18F-FDG-PET Uptake 12 Weeks After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Predicts Local Control [J].

Bollineni, Vikram Rao ;

Widder, Joachim ;

Pruim, Jan ;

Langendijk, Johannes A. ;

Wiegman, Erwin M. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (04) :E551-E555

← 1 2 3 4 5 6 7 8 9 →